Position in NERV
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$9,974,387
+$3,319,277 QoQ
Shares Held
1,655,500
0.0% QoQ
Ownership
3.55%
of shares outstanding
% of Portfolio
2.39%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NERV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Spruce Street Capital LP holds $353,870,762 across 24 Biotechnology names. NERV ranks #13 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLMD |
Relmada Therapeutics, Inc.
|
6,262,114 | $43,584,313 | |
| 2 | LBRX |
Lb Pharmaceuticals Inc
|
1,376,159 | $33,936,080 | |
| 3 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
373,274 | $31,325,154 | |
| 4 | ANRO |
Alto Neuroscience, Inc.
|
1,325,210 | $29,790,720 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
2,984,125 | $29,692,043 | |
| 6 | CNTA |
Centessa Pharmaceuticals plc
|
489,849 | $19,456,802 | |
| 7 | SVRA |
Savara Inc
|
3,383,175 | $18,472,135 | |
| 8 | KALV |
KalVista Pharmaceuticals, Inc.
|
897,681 | $18,070,318 |
All Filings in NERV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,974,387 | 1,655,500 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $6,655,110 | 1,655,500 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||